- Trial Phase
- Phase 3 (pivotal topline complete; BLA submission planned)
- Time to Market
- BLA submission expected Q3 2026; potential FDA accelerated approval guided to 2H 2027 (~1 year out, per company guidance)
- Why 6/10
- Next hard, dated catalyst is the company-guided RGX-202 BLA submission initiation in Q3 2026 (imminent, within ~6 weeks), followed by a potential FDA accelerated-approval decision guided to 2H 2027; because RGX-202 is a major but not sole value driver (sura-vec wet-AMD topline Q4 2026, RGX-121 resubmission) and the approval date is guidance rather than a set PDUFA, impactScore is 6.
Watch for the RGX-202 BLA submission announcement in Q3 2026 and FDA acceptance thereafter — that sets the review clock toward a possible 2H 2027 accelerated approval. The analyst mean price target of $22.80 (vs ~$12 now) assumes approval, so monitor FDA's willingness to accept microdystrophin expression as a surrogate (the agency's Feb 2026 CRL on REGENXBIO's RGX-121 cited surrogate-endpoint concerns) and watch for further dilution, as the July 2026 offering already added ~17-20% to share count.
Price Chart
Executive Summary
RGX-202 is REGENXBIO's (Nasdaq: RGNX) Phase 3 gene therapy for Duchenne muscular dystrophy, and its pivotal AFFINITY DUCHENNE study hit its primary endpoint with high statistical significance (p<0.0001; 93% of patients reached >10% microdystrophin expression) with a functional-improvement correlation, per the company's May 14, 2026 release. Management says a BLA submission will begin in Q3 2026 with potential accelerated approval in 2H 2027. The stock (~$12, 52-wk range $5.46-$16.19) already carries a bullish analyst setup (17 buy/strong-buy ratings vs 2 holds; mean PT $22.80), but the company burned cash, diluted holders ~17-20% in a July 2026 offering, and operates under an FDA that recently CRL'd its RGX-121 over surrogate-endpoint concerns — so the net read is mixed.
How It Works
RGX-202 is a one-time gene therapy for Duchenne muscular dystrophy (DMD), a fatal muscle-wasting disease in boys caused by mutations in the dystrophin gene. It uses an engineered AAV "NAV" vector to deliver a next-generation, shortened version of the dystrophin gene (microdystrophin) into muscle cells, enabling them to make a functional protein they otherwise lack. The pivotal trial's primary endpoint measured how much microdystrophin patients produced after one infusion (a surrogate for benefit), with a secondary read on functional improvement (NSAA score).
Trial Status
Positive topline from the pivotal Phase 3 AFFINITY DUCHENNE study announced May 14, 2026: primary endpoint met with high statistical significance (p<0.0001), with 93% of patients achieving >10% microdystrophin expression and a statistically significant correlation between expression and functional improvement (NSAA, n=9), supporting a potential accelerated approval pathway. Per the Q2 2026 report, BLA submission is on track to begin Q3 2026, enrollment in the confirmatory trial is continuing, and potential accelerated approval is guided to 2H 2027.
The Two-Sided Case
Upcoming Catalysts
- RGX-202 BLA submission initiation, company-guided Q3 2026 (within weeks)
- FDA BLA acceptance / PDUFA date setting after submission
- Potential FDA accelerated-approval decision, guided to 2H 2027
- Company-level, not RGX-202: sura-vec (ABBV-RGX-314) wet-AMD ATMOSPHERE/ASCENT topline data Q4 2026; RGX-121 BLA resubmission Q3 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
REGENXBIO Inc. Press Release RGNX ·Originating report